Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review

Abstract

Background: The aim of this paper was to perform a systematic review and, when feasible, a meta-analysis of randomized controlled trials (RCT) which used benzodiazepines (BZD) as a monotherapy versus placebo, antidepressant drugs (AD), or both. Methods: Keyword searches were conducted for identifying RCT comparing BZD and AD, and/or placebo in the treatment of depression, using electronic databases from their inception up to April 2017. We selected reports of RCT in which BZD were compared to AD and/or placebo in the treatment of adult patients with a primary diagnosis of depressive disorder or anxious depression. When feasible, data were subjected to meta-analysis. Results: A total of 38 studies met the criteria for inclusion and were then included in the systematic review. Only 1 study concerned a newer AD, fluvoxamine. For the meta-analysis, we submitted data on response rate from 22 RCT, considering BZD versus placebo (8 comparisons) and BZD versus tricyclic antidepressants (TCA) (20 comparisons). There was a lack of significant differences as to response rate between BZD and placebo, as well as between BZD and TCA. Analysis of individual studies disclosed that, in more than half of the studies comparing BZD to TCA and/or placebo, BZD were significantly more effective than placebo and as effective as TCA. Conclusions: BZD are a therapeutic option in anxious depression and there are no indications that AD are preferable. There is a pressing need for RCT of adequate methodological quality and follow-up comparing BZD to second-generation AD and placebo in anxious depression.

Exploring characteristics associated with first benzodiazepine prescription in patients with affective disorders and related diagnoses

“…Actually, Bushnell and colleagues showed, in a large sample of 765 depressed patients, no significant clinical differences in continuation of antidepressant treatment between simultaneous administration of BZDs plus antidepressant and antidepressant alone (Bushnell et al, ; Rizvi, Sproule, Gallaugher, McIntyre, & Kennedy, ). It needs also to be taken into account that, contrary to guidelines recommendations, a recent review found no significant differences in acute treatment response (up to 12 weeks) between BZDs and tricyclic antidepressants in patients with depressive disorders (Benasi et al, ). Nonetheless, it is important to stress that mood disorders often exhibit a chronic course with multiple episodes, making the choice of treatment particularly relevant beyond the short‐term.…”

Benzodiazepines or related drugs and risk of pneumonia: A systematic review and meta‐analysis

“…Benzodiazepines and related drugs (BZRDs) are commonly used to treat diverse psychiatric disorders, including depression, anxiety, insomnia, and panic attacks . These drugs are frequently prescribed in clinical practice for the general population, and the prevalence of BZRD use among the elderly is as high as 40% .…”

Effect of ramelteon coadministered with antidepressant in patients with insomnia and major depressive disorder: an exploratory study

“…In elderly subjects in Japan, those with sleep-onset insomnia were more likely to experience depression 3 years later [28]. Benzodiazepines are often used concomitantly with antidepressants to treat anxiety, and have been reported to be as effective as monotherapy in the treatment of anxious depression [29]. As sleep-onset insomnia often correlates with anxiety, anxiolytic benzodiazepines may potentially shorten sleep latency.…”